Qrons Inc.

Equities

QRON

US74737F1012

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 12:55:39 2024-03-08 pm EST			5-day change	1st Jan Change
0.1855 ^USD	-11.68%		-.--%	-19.35%

Apr. 15	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 14, 2020 at 02:55 pm EDT

Qrons Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 13,589 compared to USD 199,157 a year ago. Net loss was USD 16,731 compared to USD 217,583 a year ago. Basic eps - continuing operations was USD 0 compared to basic loss per share from continuing operations of USD 0.02 a year ago. For the half year, operating loss was USD 232,527 compared to USD 462,671 a year ago. Net loss was USD 256,863 compared to USD 479,044 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.04 a year ago.

Latest news about Qrons Inc.

Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Qrons Inc. Announces the Filing of A Provisional Patent Application in Furtherance of Its Neuronal and Infectious Disease Treatments Development, Including Sepsis	23-08-14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Qrons Files U.S. National Phase of Its Patent Application in Furtherance of Its Qs200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels	23-03-22	CI
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis	22-12-14	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	22-03-10	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Qrons Inc. announced that it has received $0.115 million in funding from Quick Capital, LLC	21-06-14	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Qrons Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Qrons Inc. announced that it has received $0.1 million in funding	20-09-22	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Qrons Inc. announced a financing transaction	20-08-10	CI
Qrons Inc. cancelled the transaction announced on May 21, 2019	20-05-20	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI

Chart Qrons Inc.

Duration

Period

More charts

Company Profile

Qrons Inc. is a biotechnology company. The Company is focused on developing biotech products, treatments, and technologies that create a platform to combat neuronal diseases. It leverages its research with developing technologies in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells, and tissue engineering for deployment in the fight against neuronal diseases. The Company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary anti-brain inflammation synthetic hydrogel and modified mesenchymal stem cells (MSCs). Its QS100TM is an injury-specific, 3D printable, implantable MSCs-synthetic hydrogel to treat penetrating brain injuries, such as gunshot wounds, motor vehicle accidents, and falls. Its QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused axonal injuries commonly referred to as concussions.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QRONS INC.	-19.35%	2.53M
MODERNA, INC.	+18.08%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+0.55%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.82%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.15B
BIO-TECHNE CORPORATION	+3.81%	12.55B
MEDPACE HOLDINGS, INC.	+28.49%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.38%	11.82B

Other Biotechnology & Medical Research